Anixa Biosciences, Inc.

NasdaqCM:ANIX Stok Raporu

Piyasa değeri: US$117.8m

Anixa Biosciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anixa Biosciences has a total shareholder equity of $20.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $22.9M and $2.2M respectively.

Anahtar bilgiler

0%

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranın/a
NakitUS$20.75m
EşitlikUS$20.69m
Toplam yükümlülüklerUS$2.22m
Toplam varlıklarUS$22.91m

Son finansal sağlık güncellemeleri

Recent updates

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

Sep 12
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely

May 23
We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely

We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

Jan 19
We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Oct 06
We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Apr 27
Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

Jan 13
Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Sep 26
We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial

Aug 15

Anixa to get additional US patent linked to breast cancer vaccine technology

Jul 21

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Jun 13
Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

May 11

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Feb 24
We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

Oct 28
Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

Our First Look At Anixa Biosciences

Sep 23

Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

Jun 12
Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

OntoChem assigns Anixa covid-19 drug discovery project to MolGenie

May 07

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Jan 13
Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact

Dec 01

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ANIX's short term assets ($22.7M) exceed its short term liabilities ($2.0M).

Uzun Vadeli Yükümlülükler: ANIX's short term assets ($22.7M) exceed its long term liabilities ($213.0K).


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ANIX is debt free.

Borcun Azaltılması: ANIX had no debt 5 years ago.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ANIX has sufficient cash runway for more than a year based on its current free cash flow.

Tahmini Nakit Akışı: ANIX has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 7.8% each year.


Sağlıklı şirketleri keşfedin